- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04197921
Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD)
March 4, 2024 updated by: InSightec
A Feasibility Clinical Trial of Exablate for Low Intensity Focused Ultrasound Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Abuse Disorders (SUDs)
The purpose of this clinical trial is to investigate Low Intensity Focused Ultrasound (LIFU) using the Exablate® Model 4000 Type 2.0/2.1 as an adjunctive neuromodulatory treatment for OUD (Opioid Use Disorder) by assessing its safety and tolerability in subjects with OUD.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
23
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Huan Bien
- Phone Number: +1-657-550-9284
- Email: huanb@insightec.com
Study Contact Backup
- Name: Julia Zhu
- Email: juliaz@insightec.com
Study Locations
-
-
Virginia
-
Morgantown, Virginia, United States, 26506
- Recruiting
- West Virginia University: Rockefeller Neuroscience Institute
-
Sub-Investigator:
- Marc Haut, PhD
-
Sub-Investigator:
- James Mahoney, PhD
-
Principal Investigator:
- Ali Rezai, MD
-
Contact:
- Jennifer Marton
- Phone Number: 304-293-5886
- Email: jennifer.marton@hsc.wvu.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Males and non-pregnant females, age 18 - 60 years old
- Subject meets DSM-5 criteria for OUD and/or other SUDs including alcohol (assessed via the SCID-5) of at least two years duration
- Subject is currently receiving outpatient treatment from the WVU Comprehensive Opioid Addiction Treatment Program (COAT), Intensive Outpatient Program (IOP) or any other program which implements the COAT model; residential or inpatient treatment from the WVU Center for Hope and Healing or an affiliated WVU hospital; or receiving outpatient/inpatient/residential treatment from similar programs that are well known to the research team. If the subject is prescribed medication for AUD or OUD (e.g. buprenorphine-naloxone, naltrexone), they will be on a stable dose of the medication for the 7 days prior to the procedure. Stable is defined as within the therapeutic range but does not require same exact dose for 7 days.
- Subject has been off opioids and other illicit substances, except for cannabis, confirmed via urine toxicology screen
- The NAc is apparent on MRI such that treatment targeting can be performed directly (visible on MRI) and indirectly (using other anatomical structures for measurements)
- Subject is able to communicate sensations during the Exablate Transcranial procedure
- Subject is willing to cooperate with the study requirements including compliance with the regimen and completion of all study visits
- Subject is able to make own medical decisions as determined by the clinical team
- Subject has signed and received a copy of the approved informed consent form
Exclusion Criteria:
- Subjects who are taking medications which may adversely interact with MOUD (See Appendix B for full list). Being on one of these medications would not automatically exclude a participant from study participation, does not automatically exclude a prospective subject from study participation. If a prospective or current subject is taking any medication listed in Appendix B, the study investigator is responsible for determining whether the subject is eligible for inclusion or continued study participation."
- Subject with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices
- Subject with known intolerance or allergies to the MRI contrast agent gadolinium (GADOVIST®)
- Subject who are unable or unwilling to tolerate the required prolonged stationary position during treatment (approximately 2-3 hours)
- More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp
- Subject with implanted objects in the skull or the brain
- Subject diagnosed with advanced kidney disease or on dialysis
- Subject with impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2
Subject with known unstable cardiac status or severe hypertension including:
- Documented myocardial infarction within six months of enrollment
- Unstable angina on medication
- Unstable or worsening congestive heart failure
- Left ventricular ejection fraction below the lower limit of normal
- History of a hemodynamically unstable cardiac arrhythmia
- Cardiac pacemaker
- Severe hypertension (diastolic BP > 100 on medication)
- Subject with history of abnormal bleeding, hemorrhage, or coagulopathy
- Subject receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure
- Abnormal coagulation profile (PLT < 100,000/μl), PT (>13.9 sec) or PTT (>37.5 sec), and INR > 1.2. If values are outside the range of normal limits, any clinically significant value may be excluded as determined by a study investigator.
- Subject with cerebrovascular disease as determined by MRI according to the Fazekas criteria. Grades II and III on the Fazekas scale should be excluded
- Past or present diagnosis of schizophrenia, psychotic disorder, bipolar disorder, or untreated depression other than one determined to be substance induced (assessed via SCID-5)
- Score of greater than 17 on the Hamilton Depression Rating Scale (HAM-D) or increased risk of suicide based on any positive response regarding passive or active suicidal ideation with or without intent over the past 3 months or lifetime history of active suicidal ideation with intent on the Columbia-Suicide Severity Rating Scale (C-SSRS) at baseline
- History of suicide attempt
- Parental history of completed suicide
- Subject meet the criteria for Cluster A or B Personality Disorders (assessed via SCID-5-PD)
- Diagnosis of dementia or any other disorder which has led to a clinically significant cognitive impairment (assessed via NIHTB-CB)
- Subject with brain tumors
- Subject with chronic pulmonary disorders e.g. severe emphysema, pulmonary vasculitis, or other causes of reduced pulmonary vascular cross-sectional area
- Any known CNS infection or infection with the Human Immunodeficiency Virus (HIV) or Hepatitis C (HCV). A diagnosis of Hepatitis C (HCV) alone is not exclusionary as long as hepatic function laboratory values are deemed not clinically significant by a study investigator and are ≤ 1.5 times the upper limit of normal.
- Subject who has had deep brain stimulation or a prior stereotactic ablation of the NAc, basal ganglia or thalamus
- Subject who has been administered botulinum toxins into the arm, neck, or face for 5 months prior to baseline
- Subject who is currently participating in another clinical investigation with an active treatment arm
- Subject unwilling to abstain from illicit substance use during the course of the study
- Subject is considered to be a poor surgical or study candidate, which may include, but is not limited to the following: any medical, social, or psychological problem that could complicate the required procedures and evaluations of the study in the judgment of the investigator
- Subject is non-English speaking
- Subject is pregnant or planning to be pregnant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Sham/Active ExAblate Treatment Stage 1 and 2
Subject will undergo both Treatment 1 (sham) and Treatment 2 (with enhanced intensity).
Subjects are blinded to the order of the sham vs active treatment.
|
There are two treatment stages.
In both stages, the subject will receive both the sham and active ExAblate treatment, and be evaluated for 90 days post-treatment for adverse events.
During Stage 1 the subject will receive the moderate intensity Exablate LIFU procedure.
During Stage2, the subject will receive the enhanced intensity ExAblate LIFU procedure.
The subjects are blinded as to the order of the sham vs active treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of Treatment Emergent Adverse Events
Time Frame: Post-ExAblate Procedure through 4 Month Follow-Up
|
Safety will be assessed by recording all adverse events that are treatment related.
Each Adverse Event will be documented for patterns of occurence.
|
Post-ExAblate Procedure through 4 Month Follow-Up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 27, 2019
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
July 1, 2025
Study Registration Dates
First Submitted
December 9, 2019
First Submitted That Met QC Criteria
December 11, 2019
First Posted (Actual)
December 13, 2019
Study Record Updates
Last Update Posted (Estimated)
March 5, 2024
Last Update Submitted That Met QC Criteria
March 4, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OUD001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid-use Disorder
-
Aurora Health CareUniversity of Chicago; University of California, Santa Cruz; Rogers Behavioral...RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine AbuseUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorder | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorders | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Vanderbilt University Medical CenterCompletedOpioid Use | Opioid-use DisorderUnited States
-
Albert Einstein College of MedicineNational Institute on Drug Abuse (NIDA); Pfizer; National Institutes of Health...Active, not recruitingTobacco Use Disorder | Opioid-use DisorderUnited States
-
Indiana UniversityCompletedOpioid Use | Opioid-use DisorderUnited States
-
New York State Psychiatric InstituteColumbia University; Weill Medical College of Cornell University; National Institute... and other collaboratorsActive, not recruitingOpioid Use | Opioid Court Model | Medication to Treat Opioid Use DisorderUnited States
-
Brigham and Women's HospitalOhio State UniversityActive, not recruitingOpioid Dependence | Opioid Use | Opioid-use DisorderUnited States
-
University of ZurichCompletedOpioid Use, Unspecified With Other Opioid-induced DisorderSwitzerland
Clinical Trials on Exablate Model 4000 Type 2.0/2.1
-
Mayo ClinicRecruiting
-
InSightecActive, not recruiting
-
University of North Carolina, Chapel HillFocused Ultrasound FoundationRecruitingPartial Seizures With Secondary GeneralizationUnited States
-
InSightecRecruitingGlioma | Glioblastoma | Liquid BiopsyUnited States, Canada
-
InSightecSuspended
-
Ali RezaiInSightecRecruitingMild Cognitive Impairment | Alzheimer Disease 1United States
-
Assistance Publique - Hôpitaux de ParisActive, not recruiting
-
SonALAsense, Inc.RecruitingDiffuse Intrinsic Pontine Glioma | Diffuse Midline GliomaUnited States
-
SonALAsense, Inc.Active, not recruitingRecurrent GBMUnited States